SAPHNELO anifrolumab 300 mg concentrated injection vial

AstraZeneca Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 3301cc4df19dc217
Product Name: SAPHNELO anifrolumab 300 mg concentrated injection vial
Artg Id: 350930
Artg Name: SAPHNELO anifrolumab 300 mg concentrated injection vial
Sponsor: AstraZeneca Pty Ltd
Company Detail Path: /organization/astrazeneca-pty-ltd
Artg Date: 2022-03-29
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/b8365f93468eea27b7e59416160a7ba7.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/d375ad23d1520a3068d460a2ff8752bd.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

3301cc4df19dc217

Type

Standard